August 2011
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p5
Trade Publication
The article discusses a collaboration between pharmaceutical firms Evotec AG and UCB to treat central nervous system (CNS) disorders. In August 2011, the two entered a three year agreement to identify small molecule modulators of priority biological targets which UCB selected. Evotec will use their integrated drug discovery expertise to target these molecules, receiving a fixed fee during the period, as well as royalties on net sales from any drugs developed during the collaboration.


Related Articles

  • Evotec enters into integrated drug discovery collaboration with UCB.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p19 

    The article announces that Evotec AG has entered into a three year integrated discovery collaboration with UCB SA to identify molecule moderators of priority biological targets involved in central nervous system (CNS) disorders.

  • UCB: Strong Future for Peptide-Based Therapies. Scott, Alex // Chemical Week;12/11/2002, Vol. 164 Issue 48, p27 

    Presents information on the prediction of Braine-l' Alleud, Belgium-based UCB-Bioproducts regarding the sales growth of peptide-based active pharmaceutical ingredients. Applications of peptide-based therapies; Reason behind the growth of peptide-based therapies.

  • Other News To Note.  // BioWorld Today;5/26/2011, Vol. 22 Issue 102, p3 

    This section offers world news briefs on the activities of several biotechnological companies, including the drug discovery platforms of Evotec AG and PsychoGenics Inc., Phylomer peptides identified by Phylogica Ltd., and preclinical data on defensin-mimetic antimicrobial compounds reported by...

  • Pharma: Clinic Roundup.  // BioWorld Today;12/5/2012, Vol. 23 Issue 235, p8 

    This article presents an update on the clinical trial of UCB SA's epilepsy drug Vimpat as of December 5, 2012.

  • Biotechnology Company Deals With Other Biotechnology Companies: June 1 - July 15, 2011.  // BioWorld Insight;7/18/2011, Vol. 19 Issue 29, p7 

    The article offers information on several deals among biotechnology companies from June 1 to July 15, 2011. It includes the collaboration between Advanced Cell Technology Inc. and Roslin Cells Ltd. to establish a human embryonic stem cell line bank in June. Deals in July include the agreement...

  • Other News To Note.  // BioWorld Today;10/6/2011, Vol. 22 Issue 194, p2 

    This section offers news briefs on the biotechnology industry. A 20 million dollar payment will be received by Agios Pharmaceuticals Inc. from Celgene Corp. A new drug application for ridaforolimus in metastatic soft-tissue or bone sarcomas from Ariad Pharmaceuticals Inc. and Merck & Co. Inc....

  • Pharma: Clinic Roundup.  // BioWorld Today;6/11/2012, Vol. 23 Issue 112, p3 

    The article reports on the impact of Cimzia (certolizumab pegol) of UCB SA on rheumatoid arthritis (RA) patients, according to data from a post-hoc analysis of the Phase IIIb RA Evaluation in Subjects Receiving Tumor Necrosis Factor (TNF) Inhibitor Certolizumab Pegol) study.

  • UCB: IV Keppra gets EU regulatory nod.  // PharmaWatch: CNS;Jun2006, Vol. 5 Issue 6, p5 

    The article reports on the recommendation of the European Agency for the Evaluation of Medicinal Products that the intravenous (IV) Keppra drug of UCB be used in juvenile myoclonic epilepsy. The European Commission approved the IV formulation of Keppra for use as adjunctive therapy in the...

  • Other News To Note.  // BioWorld International;7/13/2011, Vol. 16 Issue 28, p2 

    This section offers news briefs on the biotechnology industry. BioLineRx Ltd. is planning to list its shares through American Depositary Receipts to be traded on Nasdaq under the ticker BLRX. A collaboration has been signed by Evotec AG with UCB SA to discover small-molecule modulators of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics